Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up
LG

LGND

Market Closed

Ligand Pharmaceuticals Incorporated

NASDAQHealthcareBiotechnology
US
47 employees
CEO: Todd C. Davis
Founded: 1992
$307.82
+$0.00(+NaN%)
Market Cap
6.14B
Beta
1.01
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Ligand Pharmaceuticals shows a high PERT-weighted fair value ($622.84) more than double its current price, indicating undervaluation with strong financial health (4.20/5). However, Monte Carlo analysis reveals substantial downside risk (100% scenarios below current price) and high volatility (37.72% CV). Valuation methods diverge significantly, reflecting uncertainty amid growth potential.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore LGND

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

LGND in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms